Скачать или смотреть Glucotrack CEO Paul Goode Shares Latest Developments with Benzinga

Glucotrack CEO Paul Goode recently sat down with Dan Leach of Benzinga, a leading financial news platform, to share exciting updates about the company’s groundbreaking continuous blood glucose monitoring (CBGM) technology. The conversation spotlighted the successful completion of Glucotrack’s first human clinical study, which confirmed the safety of the device’s placement, use, and removal. Designed to monitor glucose levels directly from the bloodstream for up to three years without external wearable components, this innovative system promises greater simplicity, accuracy, and discretion for diabetes management.

Paul Goode also discussed Glucotrack’s plans for upcoming trials to refine the technology, improve sensor accuracy, and ensure long-term reliability. This milestone marks a significant step forward in revolutionizing diabetes care with a focus on convenience and improved quality of life for patients.

Stay up to date at glucotrack.com!